Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion type Assertion NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_head.
- NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion description "[Furthermore, treatment of ErbB2(KI) or human ERBB2-overexpressing tumor cells with a selective ?-catenin/CBP inhibitor significantly decreased proliferation and ErbB2 expression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_provenance.
- NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion evidence source_evidence_literature NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_provenance.
- NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion SIO_000772 23720052 NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_provenance.
- NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion wasDerivedFrom befree-2016 NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_provenance.
- NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_assertion wasGeneratedBy ECO_0000203 NP1081790.RAr6Knju1qE3cd6ZxSNcM-TX-IcaL2nBRd1dZNQOIZTPU130_provenance.